Cancer immunotherapy shows long-term promise in lung cancer

	Tweet

New, long-term results from a clinical trial presented today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery—to the same extent as chemotherapy but without the side-effects of chemotherapy.

Prof. Johan Vansteenkiste from University Hospital Gasthuisberg in Belgium described the results after 44-months follow-up from a double-blind, placebo-controlled trial in 182 patients with non-small-cell lung cancer—the most common form of the disease.

After complete surgical resection of the tumor, patients were randomly assigned to receive either placebo injections or injections of MAGE-A3 ASCI administered over 27 months (five given at three-week intervals followed by eight given once every three months). MAGE-A3 is a tumor-specific antigen, expressed in 35-50% of non-small-cell lung cancer, but not on normal cells.

"The aim is to help the body immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3,” explains Prof. Vansteenkiste. “In other words, it is a kind of treatment method that makes the body immune system specifically attack the lung cancer cells.”

After 44 months, 69 of 182 patients had experienced a recurrence of their cancer, including 57 deaths. Those given the MAGE-A3 injections had longer on average before their cancer recurred, were less likely to have any recurrence, and were less likely to die.

“Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection about 50% will relapse and die from their cancer,” says Prof. Vansteenkiste. “Postoperative chemotherapy is able to improve cure rates, but is sometimes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy. This is why the signal from this phase II randomized study is important: the reduction in risk of postoperative cancer relapse is similar to the one obtained with postoperative chemotherapy, while the side-effects of this new strategy are minimal compared to chemotherapy.”

Most patients only experience mild reactions at the injection site and fever within 24 hours of the injection, he explained. “Therefore, it is suitable for long-term maintenance treatment and for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment.” A large Phase III trial of the therapy, named MAGRIT, is now underway.

Contact: Vanessa Pavinato

41-919-731-907
European Society for Medical Oncology

RELATED STORIES:
Proton Therapy Safe, Effective for Early-Stage Lung Cancer Patients   Faster Tracking of Lung Tumors May Help Treatment   Estrogen-only therapy may not up lung cancer deaths   New clinical trial for patients with asbestos-associated lung cancer   Lack of Sunlight May Increase Lung Cancer Risk   Simple blood test detects lung cancer before it’s too late   Researchers Identify Tumor-Suppressor Gene for Lung Cancer   Value of CT screening for lung cancer unclear   Early morning smokers have increased risk of lung and head and neck cancers   An “HIV-test” Equivalent for the Early Detection of Lung Cancer   Quick, easy test identifies aggressive type of lung cancer in never-smokers   Cigar, pipe smoking may raise lung disease risk, too   New lung cancer research finds half of advanced lung cancer patients receive chemotherapy   BATTLE Trial Personalizes Lung Cancer Therapy   Red wine may ward off lung cancer: study   Last-minute radiation saves lung cancer patients   Researchers Identify Specific Lung Cancer Susceptibility Gene   University of Colorado Cancer Center test helps reduce risk of death in advanced lung cancer   Novel animal model of lung adenocarcinoma   Lung cancer tied to family risk of other cancers   Blood test may find early lung cancer: study   Positive CT scan for lung cancer may resolve

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]